company background image
GLAX

GlaxoSmithKline PharmaceuticalsNSEI:GLAXO Stock Report

Market Cap

₹248.8b

7D

-0.9%

1Y

-2.7%

Updated

21 Oct, 2021

Data

Company Financials +
GLAXO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance4/6
Financial Health5/6
Dividends4/6

GLAXO Overview

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally.

GlaxoSmithKline Pharmaceuticals Competitors

Sun Pharmaceutical Industries

NSEI:SUNPHARMA

₹2.0t

Dr. Reddy's Laboratories

BSE:500124

₹771.0b

Cipla

NSEI:CIPLA

₹735.3b

Cadila Healthcare

NSEI:CADILAHC

₹522.7b

Price History & Performance

Summary of all time highs, changes and price drops for GlaxoSmithKline Pharmaceuticals
Historical stock prices
Current Share Price₹1,468.70
52 Week High₹1,376.00
52 Week Low₹1,767.40
Beta0.19
1 Month Change-2.41%
3 Month Change-12.67%
1 Year Change-2.72%
3 Year Change14.68%
5 Year Change0.43%
Change since IPO549.65%

Recent News & Updates

Mar 20
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

It hasn't been the best quarter for GlaxoSmithKline Pharmaceuticals Limited ( NSE:GLAXO ) shareholders, since the share...

Feb 27
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Is GlaxoSmithKline Pharmaceuticals Limited ( NSE:GLAXO ) a good dividend stock? How can we tell? Dividend paying...

Shareholder Returns

GLAXOIN PharmaceuticalsIN Market
7D-0.9%-3.5%-1.0%
1Y-2.7%20.0%63.7%

Return vs Industry: GLAXO underperformed the Indian Pharmaceuticals industry which returned 20% over the past year.

Return vs Market: GLAXO underperformed the Indian Market which returned 63.7% over the past year.

Price Volatility

Is GLAXO's price volatile compared to industry and market?
GLAXO volatility
GLAXO Beta0.19
Industry Beta0.60
Market Beta1

Stable Share Price: GLAXO is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: GLAXO's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19244,283Sridhar Venkateshhttps://india-pharma.gsk.com

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, gastrointestinal, nutrition, dermatology, respiratory, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Betnovate, Calpol, Ceftum, and Synflorix brands.

GlaxoSmithKline Pharmaceuticals Fundamentals Summary

How do GlaxoSmithKline Pharmaceuticals's earnings and revenue compare to its market cap?
GLAXO fundamental statistics
Market Cap₹248.81b
Earnings (TTM)₹3.68b
Revenue (TTM)₹33.40b

67.5x

P/E Ratio

7.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GLAXO income statement (TTM)
Revenue₹33.40b
Cost of Revenue₹13.87b
Gross Profit₹19.53b
Expenses₹15.85b
Earnings₹3.68b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Oct 29, 2021

Earnings per share (EPS)21.75
Gross Margin58.48%
Net Profit Margin11.03%
Debt/Equity Ratio2.3%

How did GLAXO perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

138%

Payout Ratio

Valuation

Is GlaxoSmithKline Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

67.54x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: GLAXO (₹1468.7) is trading above our estimate of fair value (₹477.84)

Significantly Below Fair Value: GLAXO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GLAXO is poor value based on its PE Ratio (67.5x) compared to the Indian Pharmaceuticals industry average (24.9x).

PE vs Market: GLAXO is poor value based on its PE Ratio (67.5x) compared to the Indian market (21.5x).


Price to Earnings Growth Ratio

PEG Ratio: GLAXO is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: GLAXO is overvalued based on its PB Ratio (16.6x) compared to the IN Pharmaceuticals industry average (3.1x).


Future Growth

How is GlaxoSmithKline Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

32.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLAXO's forecast earnings growth (32% per year) is above the savings rate (6.7%).

Earnings vs Market: GLAXO's earnings (32% per year) are forecast to grow faster than the Indian market (18.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GLAXO's revenue (10.8% per year) is forecast to grow slower than the Indian market (12.8% per year).

High Growth Revenue: GLAXO's revenue (10.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GLAXO's Return on Equity is forecast to be high in 3 years time (38%)


Past Performance

How has GlaxoSmithKline Pharmaceuticals performed over the past 5 years?

-13.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GLAXO has a large one-off loss of ₹1.7B impacting its June 30 2021 financial results.

Growing Profit Margin: GLAXO's current net profit margins (11%) are higher than last year (2.9%).


Past Earnings Growth Analysis

Earnings Trend: GLAXO's earnings have declined by 13.1% per year over the past 5 years.

Accelerating Growth: GLAXO's earnings growth over the past year (307.1%) exceeds its 5-year average (-13.1% per year).

Earnings vs Industry: GLAXO earnings growth over the past year (307.1%) exceeded the Pharmaceuticals industry 35.8%.


Return on Equity

High ROE: GLAXO's Return on Equity (24.6%) is considered high.


Financial Health

How is GlaxoSmithKline Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: GLAXO's short term assets (₹22.0B) exceed its short term liabilities (₹13.3B).

Long Term Liabilities: GLAXO's short term assets (₹22.0B) exceed its long term liabilities (₹2.8B).


Debt to Equity History and Analysis

Debt Level: GLAXO's debt to equity ratio (2.3%) is considered satisfactory.

Reducing Debt: GLAXO's debt to equity ratio has increased from 0.1% to 2.3% over the past 5 years.

Debt Coverage: GLAXO's debt is well covered by operating cash flow (1669%).

Interest Coverage: GLAXO earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is GlaxoSmithKline Pharmaceuticals's current dividend yield, its reliability and sustainability?

2.04%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: GLAXO's dividend (2.04%) is higher than the bottom 25% of dividend payers in the Indian market (0.34%).

High Dividend: GLAXO's dividend (2.04%) is in the top 25% of dividend payers in the Indian market (1.38%)


Stability and Growth of Payments

Stable Dividend: GLAXO's dividend payments have been volatile in the past 10 years.

Growing Dividend: GLAXO's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (137.9%), GLAXO's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: GLAXO's dividends in 3 years are forecast to be covered by earnings (66.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Sridhar Venkatesh

1.5yrs

Tenure

₹82,146,000

Compensation

Mr. Sridhar Venkatesh serves as Managing Director at GlaxoSmithkline Pharmaceuticals Limited since April 1, 2020. Mr. Venkatesh served as the Commercial Head of Pharmaceuticals at GlaxoSmithkline Pharmaceu...


CEO Compensation Analysis

Compensation vs Market: Sridhar's total compensation ($USD1.10M) is above average for companies of similar size in the Indian market ($USD587.75K).

Compensation vs Earnings: Insufficient data to compare Sridhar's compensation with company performance.


Leadership Team

Experienced Management: GLAXO's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: GLAXO's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

GlaxoSmithKline Pharmaceuticals Limited's employee growth, exchange listings and data sources


Key Information

  • Name: GlaxoSmithKline Pharmaceuticals Limited
  • Ticker: GLAXO
  • Exchange: NSEI
  • Founded: 1924
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹248.807b
  • Shares outstanding: 169.41m
  • Website: https://india-pharma.gsk.com

Number of Employees


Location

  • GlaxoSmithKline Pharmaceuticals Limited
  • GSK House
  • Dr. Annie Besant Road
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 18:03
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.